Skip to content

HsuanLee01/Choletrapib_Effect_on_HDL_Cholesterol

About

Analyzed data from a double-blinded RCT involving 485 dyslipidemia patients to assess Choletrapib’s impact on HDL cholesterol. Examined HDL levels at baseline, 1 year, and 2 years using ANCOVA. Observed a significant increase in HDL cholesterol in the treatment group compared to the control.

Stars

Watchers

Forks

Releases

No releases published

Packages

 
 
 

Contributors